Around the world, innovative genomic-medicine programs capitalize on singular capabilities arising from local health care systems, cultural or political milieus, and unusual selected risk alleles or disease burdens. Such individual ef orts might benef t from the sharing of approaches and lessons learned in other locales. The U.S. National Human Genome Research Institute and the National Academy of Medicine recently brought together 25 of these groups to compare projects, to examine the current state of implementation and desired near-term capabilities, and to identify opportunities for collaboration that promote the responsible practice of genomic medicine. Ef orts to coalesce these groups around concrete but compelling signature projects should accelerate the responsible implementation of genomic medicine in ef orts to improve clinical care worldwide.
T e growing number of advances in human genomic research that are directly relevant to disease diagnosis, treatment, and prevention coupled with the declining cost of genome sequencing has promoted the use of genomic technologies in routine clinical care (1) . Among the many challenges to widespread implementation of genomic medicine, what looms largest is the lack of evidence to demonstrate improved clinical or economic outcomes (2) . Other needs include standardization and quality assurance of genomic data produced by clinical laboratories, a clinical-informatics infrastructure for managing genomic information, education for health professionals and patients in using the information, and policies for data sharing that permit ongoing capture of generalizable clinical experiences in what has been termed "evidence-generating medicine" (3) . A host of ongoing ef orts exist worldwide to establish national implementation strategies for genomic medicine (table S1) (4) , but many such ef orts are being conducted in relative isolation. Sharing of strategies, data, and standards could minimize wasteful duplication and speed progress in identifying genomics-based interventions and translating them to the clinic.
To assess the current global state of the art (2), the U.S. National Human Genome Research Institute and the U.S. National Academy of Medicine convened 90 leaders in genomic medicine from the United States and 25 other countries on f ve continents for a Global Leaders in Genomic Medicine symposium in 2014 (table S1). Although the organizers attempted to identify and invite every nation working on the implementation of genomic medicine, participation was somewhat restricted by the lack of systematic information on such ef orts and limited travel funding [see full list of participating countries at www.genome.gov/27555775]. Here we summarize ef orts described by the participants, with an emphasis on (i) regions with singular capabilities because of the structures of their health care systems, cultural or political readiness for implementation, or unusual disease burdens or risk-allele frequencies; (ii) the current state of implementation in the various countries and capabilities desired over the next 3 to 5 years; and (iii) opportunities for collaboration to promote the responsible implementation of genomic medicine.
INTERNATIONAL LANDSCAPE
Early ef orts at genomic-medicine collaborations include the European Association for Predictive, Preventive, and Personalised Medicine (EPMA), the European Commission's EuroBioForum and observatory, and the Genomic Medicine Alliance (table S1) (5) , which have spearheaded promising projects such as the application of genome sequencing in pharmacogenomics and the development of online pharmacogenomic resources. Related ef orts include the International Rare Disease Research Consortium (IRDiRC), which is developing new diagnostic strategies and therapies for rare diseases; the Global Alliance for Genomics and Health (GA4GH), which promotes responsible sharing of genomic data for research (6) ; and EuroGentest (table S1), which is draf ing professional guidelines for diagnostic DNA sequencing.
In an informal poll of participants prior to the symposium, nearly all sites reported some genomic medicine capabilities, such as using genotyping or genome or exome sequencing for disease prediction, diagnosis, prevention, and treatment as well as family counseling (Table 1) . More than 70% of respondents reported the availability, in specialized centers only, of clinical genomic sequencing resources for targeted cancer treatment, rare disease diagnosis, and microbial pathogen identif cation, while ~10% reported these capabilities to be widely available. Conversely, more than half reported the lack of any capabilities for newborn genomic sequencing or RNA, metabolomics, or proteomic prof ling. Over the next 3 to 5 years, participants hope to see substantial gains in the availability of clinical genomic resources, particularly for pharmacogenomics, pathogen identif cation, genetic counseling, electronic medical records (EMRs), and clinical-decision support. Several other technologies, including newborn sequencing, rare disease diagnosis, and RNA prof ling, were projected to become available, within 3 to 5 years, in specialized centers where no capability currently exists. e barriers to global implementation of genomic medicine worldwide (Table 2 ) are similar to those identif ed in a 2012 survey that examined U.S. genomic medicine-implementation e f o r t s ( 2), reinforcing the notion that the global genomic-medicine community shares important challenges and goals. e most common implementation efforts involve cancer genomics, large-scale exome or whole-genome sequencing, and pharmacogenomics, while several current projects focus on particular geographical priorities (table S2) . National ef orts to build infrastructures for genome sequencing and other genomic and information technologies are under way in nearly all countries represented at the symposium. Perhaps the largest such ef ort is the UK project to sequence 100,000 whole genomes by 2017 through the creation of Genomics England (table S1) (7) . is project builds on a national strategy to link the National Health Service (NHS) EMRs to genomicmedicine research and development (table S1), focusing initially on NHS patients with cancer and rare and infectious diseases. e sequenced genomes will be analyzed to enhance each patient's clinical care as well as to create a research dataset linked to EMRs. Genomics England also aims to train the wider health care community in using the technology and will build secure data linkages to the NHS to ensure that the effort leads to improvements in patient care. Pilot studies of 2,000 patients with rare inherited diseases will be completed in 2015, and pilot studies of 3,000 patients with lung, breast, and colon cancer began in late 2014.
POLICY
e main study will involve the sequencing of 30,000 whole genomes per year in these three emphasis areas through 2017 and should produce a rich infrastructure of next-generation genome sequencing centers, a sample pipeline and biorepository, and large-scale data resources for producing new diagnostics and therapies.
Belgium is also building a national genome-sequencing pipeline, the Belgian medical genomics initiative (BeMGI) (table S1)-a comprehensive network of scientists and clinicians intended to boost research, translate genomics to clinical care, and prepare the next generation of researchers and clinicians to use genomic technologies. Current ef orts are devoted to collecting and sharing variant-frequency data and translating next-generation genome sequencing techniques to clinical practice (for example, in diagnosing rare or novel diseases). Similarly, the Estonian government recently approved a pilot program for personal medicine, which involves the sequencing of 5,000 Estonian genomes and the development of an Estonian-specif c genotyping array, coupled with automated decision support and training of physicians to use the results in everyday practice.
is comprehensive approach will be pilot tested in 50,000 individuals within the Estonian Biobank (8) and linked with Estonia's rich national EMR system, through which all residents of Estonia can access their personal medical information via a smartcard-based national identity card. If successful, the resulting array-based test will then be of ered to all Estonian residents ages 35 to 65 years, yielding a database of up to 500,000 individuals, each with a longitudinal EMR, genotype, and prescription data for use in disease-risk assessment and drug-response prediction as well as in biomedical research.
Israel's Clalit health system has established a national laboratory that provides all medical institutes in Israel with sequencingbased panels that assess somatic tissue and germline genomic changes for cancer disease risks and treatment responses. It is also testing extensively for founder mutations in various disease states and is developing models of primary care in which patients will be routinely tested with broad genomic panels by staf trained to interpret genomic results.
In Australia, newly developing comprehensive cancer centers are integrating genomics-based cancer research, patient care, and education while giving patients access to the latest experimental protocols and drugs. Several other countries, such as Korea and Kuwait, are pursuing more limited genome-sequencing programs, some in close collaboration with the private sector to build capacity and expertise. ese and many other participating nations expressed their willingness to deposit their resulting sequence and phenotype data in widely accessible databases such as ClinVar (9) or dbGaP (table S1) . Such sharing will not only facilitate the interpretation of human-genomic variation globally but also give external visibility to these nations' emerging programs and better integrate their scientists into the international genomics research community.
Canada's Genomics and Personalized Health competition (GAPH) is a somewhat dif erent approach to building national genomics capacity and assessing the costef ectiveness and impact of genomic technologies on patient outcomes (table S1). Seventeen projects have been funded to support genomic-medicine implementation and related research in health administration, health technology, and comparative effectiveness. Close involvement of the private sector is an important and innovative component and is ref ected in the participation of 19 biotechnology-oriented companies in the project teams. Private-sector involvement is also critical to Kuwait's Genatak sequencing initiative in which patients themselves pay for their whole-genome sequencing (table S1). Japan is implementing a program somewhat similar to Canada's GAPH in its Implementation of Genomic Medicine project to establish a network of genomicsfocused biobanks, build a comprehensive genomic-variation database, and perform studies to assess clinical ef cacy and utility of genomic information in clinical practice.
A third approach-the use of highly focused pilot programs to build capac- Need to align genomic research with the future burden of disease and health needs of patients and populations and the development of genomic tests with the development of ef ective co-dependent technologies Need to consider ethical and legal aspects of the ownership of genomic information and manage competing interests in a fair and transparent manner *A codependent health technology is one that depends on a second technology to achieve or enhance the intended ef ect, such as a diagnostic test used to determine a patient subgroup that is most likely to respond to a new medication. [www.health.gov.au/internet/hta/publishing.nsf/ Content/co-1] ○ Establish "network of networks" in policy development to share information • Costs and benef ts ○ Identify burdens of disease and points in care pathway where genomic tools would integrate and have the greatest impact on outcomes ○ Improve capacity for conducting convincing economic, feasibility, and sustainability analyses ○ Perform economic, feasibility, and sustainability analyses from perspective of dif erent stakeholders, such as payers, delivery systems, national health services ○ Engage payers and payment decision processes ○ Work in and learn from systems with one or a few centralized payers ity and demonstrate ef ectiveness before full-scale implementation-capitalizes on disproportionate disease burdens or singular capabilities within a given country. For example, Luxembourg's Centre for systems biomedicine is leveraging local expertise in neurobiology, pathway analysis, and community-driven annotation (10, 11) to create an interactive map that charts the genetic and molecular underpinnings of Parkinson's disease (12) . is map will be integrated with genome sequence data to facilitate early diagnosis and molecular stratif cation of patients. Singapore's Personalized Omic Lattice for Advanced Research and Improving Stratif cation (POLARIS) project takes advantage of local expertise and interest in genomics and ophthalmology in launching a pilot ef ort of transforming growth factor-β-induced (TGFBI) sequencing to assess genetic risk for stromal corneal dystrophies (13) . is ef ort will be followed by the implementation of a 90-gene panel that targets gastrointestinal cancersdiseases of high burden in Singapore-in a systematic ef ort to develop a nationwide framework for genetic and genomic testing. ailand's Ministry of Public Health and Ramathibodi Hospital are focusing on a condition that occurs at unusually high frequency locally and was recently shown to have strong genetic determinants. StevensJohnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a devastating and of en fatal cutaneous reaction to medications that is largely mediated by high-risk HLA alleles.
ailand has one of the highest rates of SJS/ TEN in the world, mainly attributable to a high frequency of these risk alleles and use of causative drugs. Ramathibodi hospital has launched a "pharmacogenetics card" that can be carried in a wallet and provides a patient's HLA variant information, which predicts the risk of contracting SJS/TEN from specif c drugs. Initial cost-ef ectiveness studies have been suf ciently convincing that the ai government has agreed to provide the testing as standard of care (14) . Singapore has come to the same conclusion: Asian patients who are being considered for carbamazepine treatment are of ered HLA-B*15:02 screening (15, 16) . ese three brief y described approaches-population-wide genomic sequencing and EMR integration, coordinated nationwide genomic medicine research programs, and localized ef orts that focus on unusual capabilities or needs-demonstrate that no country has a monopoly on the implementation of genomic medicine. Quite the contrary, implementation is expanding globally in diverse and highly innovative ways. Yet here again, as noted in early U.S. genomic medicine implementation programs (2), many of these ef orts are being conducted with little interaction or collaboration. Given the rapid growth of the genomics-based biotechnology sector (17) and the pressure on university-based researchers to commercialize their work (18) , some degree of competition is to be expected. Still, willingness to share ef ective tools and strategies through consortia such as the Electronic MEdical Records and GEnomics (eMERGE) network (19) , the PharmacoGenomics KnowledgeBase (PharmGKB), the Implementing GeNomics In pracTicE (IGNITE) network, and the GAPH, IRDiRC, and GA4GH ef orts described above demonstrate the possibilities for synergistic global interactions (table S1) . Indeed, the international collaborations GA4GH, IRDiRC, and GAPH, which focus predominantly on research, illustrate the potential power of such alliances and the readiness of the genomics community to form them. Given the critical need for clinical-evidence generation and evaluation of genomic medicine interventions as well as the value of harnessing information from diverse populations to capture the immensity of human genomic variation, international collaborative projects in clinical implementation are an obvious solution.
MULTINATIONAL TEAMWORK
Several areas in particular could benef t substantially from multinational collaborations in genomic-medicine implementation (Table 3) . Even when taking into account cultural dif erences as well as variations in public perception, governance structures, health care systems, resources, infrastructure, allele frequencies, and prevalent diseases, there is much to be learned and the potential for unnecessary duplication is so great that some degree of coordination and sharing of results is critical. Systematic mapping of ongoing implementation projects worldwide and an inventory of available evidence and evidence-generation projects will help to def ne gaps and reveal how a particular group can best interact with existing ef orts.
Evidence generation. Studies designed to determine the value of genomic medicine for patients, clinicians, and health care systems are among the most expensive of the potential international collaborations, and considerable work is ongoing, as detailed above. Despite dif erences in health care delivery systems, research in a variety of disciplines has demonstrated the value and relevance of data accumulated in diverse settings (20, 21) . International collaborations have amply shown the speed with which multinational consortia can answer questions that few countries can tackle on their own, as demonstrated for survival af er myocardial infarction (22) , the global burden of disease (23), and HIV/AIDS (24) . As many genomic-medicine implementation projects are already in progress, a critical f rst step is to catalog ongoing evidencegenerating projects and the genomics-based interventions that they can be used to evaluate. Such a catalog should include the availability of these projects' specimens and data, including patient data, for additional research. Registries such as the Australia and New Zealand clinical trials registry, the E.U. Clinical Trials Register, and ClinicalTrials. gov (table S1) (25) could conceivably be adapted to receive and provide information about evidence-generation projects in genomic medicine.
To f ll gaps in evidence identif ed by surveying the cataloged projects, a key next step is to identify countries and health care systems willing to enable access to patient data, within appropriate constraints of policy, privacy, and consent. Dif erences across systems-including but not limited to language-also must be evaluated to f nd those most scientif cally advantageous for combined analysis. Systems will then be needed to capture relevant outcomes from EMRs and other clinical systems and settings as well as to analyze and interpret the f ndings. Funding for these ef orts is needed, but to the degree that studies can be embedded in ongoing clinical care, costs of evidence generation might be reduced substantially (26) (27) (28) .
Another important step is to def ne standards for what constitutes suf cient evidence to implement a genomic medicine intervention, which likely will vary depending on whether a gene, genetic variant, or genetic test is under consideration and whether it would be used for risk prediction, diagnosis, treatment, or an understanding of pathogenesis. Also needed are additional standards for performance of genetic tests, with emphasis on interpretation and clinical decision support, and standards for incorporating genomic information into EMRs. Once a suf cient body of evidence is avail-able, professional organizations and policymakers will need to develop professional practice guidelines suitable to a specif c setting or country. For example, the National Health and Medical Research Councils of Australia and New Zealand are developing a framework and principles to facilitate the translation of genomic-based tests from discovery to health care (table S1) .
Health information technology. With the possible exception of imaging, few areas of medicine are as dependent on information technology (IT) as genomics, given the vastness of genome sequence data. Although sequence data can and likely should be stored and manipulated outside EMRs (29) , extracting even the clinically relevant genomic variants found in a single patient is a challenging task. Because of the rapid evolution of knowledge about clinically relevant variants and the changing clinical situation of an individual patient, a dynamic approach is needed for presenting variant information only when it can potentially make a dif erence in that individual's care (30) . In addition, genome sequence data should ideally be retrievable for use later in a patient's clinical course and throughout their lifetime and should be accessible to other specialists and care systems as needed.
A critical f rst step is to def ne the key data elements that should be stored in the EMR, so that construction of IT systems can accommodate them. Truly global resources for actionable clinical genomic variants are urgently needed and could build on current ef orts such as the Clinical Genome Resource (ClinGen) (table S1) (31) , which includes the ClinVar database of the U.S. National Center for Biotechnology Information (9) . Other federated databases necessary to interpret variants and implement genomic medicine, such as the international Exome Aggregation Consortium (ExAC) dataset (table S1) and the Sanger Institute's Database of Chromosomal Imbalance and PHenotype in humans using Ensembl Resources (DECIPHER) (32) , are needed, as is the aggregation of worldwide genomicvariant data and agreed-upon strategies to create relevant reference genome sequences where needed to underpin these resources. Use of available and widely accepted controlled vocabularies (ontologies) for phenotypes and avoidance of proliferation of local or regional ontologies will be essential to the interpretation of variants and sharing of information.
e Innovative Medicine initiative project ETRIKS, funded jointly by the European Union and industry, aims to create and run an open, sustainable research informatics and analytics platform for sharing data and supporting translational research in personalized medicine (table S1) .
Education and workforce development. Educational needs will vary by target group (Table 3) . Assessment of the currently available genomic professional workforce and estimates of workforce needsalthough likely to show shortages at almost every level in almost every country-will help to prioritize educational programs that can then be tailored to the settings in which genomics-based care will be delivered, such as through routine primary care, specialized genetic clinics, or pharmacists or other allied health personnel. Competencies need to be def ned and appropriate educational programs developed for health care professionals at multiple levels within a given system (see National Coalition for Health Professional Education in Genetics, table S1) (33) . Integration of genomics into health-professional curricula is becoming increasingly necessary, and, although translation for language and cultural appropriateness will be needed, global sharing, rather than reinventing, of ef ective training paradigms and best practices is a worthwhile endeavor. Online tools help to facilitate rapid implementation and global distribution (for example, Coursera and EuroGenTest clinical utility gene cards, table S1). Educational materials for patients, policy-makers, and regulatory agents should also be built from new and available resources, translated and customized for specif c cultures and target audiences, (34) , and dispersed through an information clearinghouse.
Pharmacogenomics. Several pharmacogenomic applications have already been widely implemented in the United States and elsewhere (1, 35, 36) and could represent an "early win" ripe for transnational sharing of best practices and lessons learned. Ef ective international collaborations have been formed to study the genomics of adverse drug reactions (37, 38) , but actual implementation ef orts have been more isolated.
e Pharmacogenomics for Every Nation Initiative (PGENI) is a notable exception, promoting integration of pharmacogenomics into public health decision-making by using population-specif c allele-frequency data for nationally tailored drug selection in developing nations (table S1). Also being used clinically are guidelines from the Pharmacogenomics research network's Clinical Pharmacogenetics Implementation Consortium (CPIC) (table S1), which provides recommendations on drug selection and dosing on the basis of an individual's genotypic data.
Collaborative implementation ef orts in pharmacogenomics could promote the generation of an improved evidence base that focuses on inexpensive drugs characterized by treatment failure, such as clopidogrel (39), or severe adverse reactions, such as abacavir (40) , likely to be limited to a genetically def ned subset of patients. e pharmacogenomics card for avoidance of SJS/TEN being implemented in ailand is an elegantly simple and practical approach for reducing the incidence of one of the most feared adverse drug reactions. Wider implementation of this approach in neighboring countries that have similar health systems and ancestries, with an ultimate aim of global eradication of genetically related SJS/TEN, appears to be an achievable goal around which an international genomicmedicine collaborative could coalesce.
Application of whole-genome sequencing in pharmacogenomics eventually could fully def ne an individual's personalized pharmacogenomics prof le (41) . Customizing such an approach in a targeted sequencing ef ort of the several hundred pharmacogenes involved in drug metabolism and transport or a smaller subset of clinically actionable pharmacogenes would reduce costs and make this application more immediately af ordable than more comprehensive sequencing ef orts (42) .
Policy and regulatory issues. Multiple international initiatives are addressing policy needs to facilitate data sharing in genomic research, particularly the Canadianled Public Population Project in genomics and Society (P 3 G) (43) and Global Alliance for Genomics and Health (GA4GH) (table S1) (14) . Such ef orts are quite relevant to genomic-medicine implementation and, as with the evidence realm, an assessment of current activities along with a gap analysis are important initial steps. Harmonizing national ethical guidelines and regulatory frameworks as feasible is essential for successful international collaborations, as is a complete understanding of regional laws that govern genomics research, privacy, and conf dentiality. To evaluate costs, risks, and benef ts of genomic interventions, one must identify diseases for which genomic tools would have the greatest impact on patient and population outcomes-such as cancers, metabolic disorders, anti-HIV therapy, or well-def ned genetic disorders such as cystic f brosis. By integrating economic assessments into translational research, scientists and clinicians can determine the utility and relative value of genomic interventions and use the data to inform clinical decisionmakers and policy-makers. Expanding single-country studies of cost-ef ectiveness to multiple health care systems, through multinational collaborations, may help to identify key structural components that promote favorable cost-benef t ratios (44) .
COMING TOGETHER
e wealth of international programs actively engaged in genomic-medicine implementation and the potential for synergy and collaboration among them present exciting opportunities for speeding knowledge generation and improving patient care. Especially in this online age, none of these projects should have to labor in isolation. Several organizations are already showing the power of the international genomics community to form ef ective collaborations around research, although most are closer to the generation of new knowledge than to implementation of that knowledge for improving patient care. Engaging and building on the ongoing work of these groups will be critical in furthering the ef ort without wasteful duplication. Coalescing these groups around concrete but compelling signature projects may have a galvanizing ef ect that will facilitate similar programs in the future.
To explore these possibilities, several participating investigators and countries have formed a Global Genomic Medicine Collaborative (G2MC; www.iom.edu/ G2MC) hosted by the U.S. National Academy of Medicine as part of its Roundtable on Translating Genomic-Based Research for Health (table S1). Goals of the G2MC are to serve as a nexus for genomic medicine activities globally, develop opportunities for global genomic-medicine implementation and outcomes research, and capture and disseminate best practices across the global community.
Recognizing that this initial survey has likely failed to capture many relevant projects and interested countries, the authors invite scientists and policy-makers who represent their governments' genomic medicine-implementation ef orts to join this collaborative by making their interests known to the authors (in particular, G.S.G., G.P.P., and J.E.L.W.). Genomic medicine has the potential to dramatically change the way medical professionals deliver health care. As we work toward realizing our common interests in the appropriate implementation of genomic medicine, it is indeed encouraging to know that none of us need to tackle these challenges alone.
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